HISTOGEN INC (HSTO) Stock Price, Quote, News and Overview
NASDAQ:HSTO - Nasdaq - US43358Y2028 - Common Stock - Currency: USD
HSTO Quote, Performance and Key Statistics
0.658
+0.15 (+29.27%)
The current stock price of HSTO is 0.658 USD. In the past month the price decreased by -1.2%. In the past year, price decreased by -55.54%.
HSTO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About HSTO
Company Profile
Histogen, Inc. engages in the development of potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The firm is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. The company develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.
Company Info
HISTOGEN INC
10655 Sorrento Valley Road, Suite 200
San Diego CALIFORNIA 92121 US
CEO: Richard W. Pascoe
Employees: 7
Company Website: https://histogen.com/
Phone: 18585263100.0
HISTOGEN INC / HSTO FAQ
What is the stock price of HISTOGEN INC today?
The current stock price of HSTO is 0.658 USD. The price increased by 29.27% in the last trading session.
What is the ticker symbol for HISTOGEN INC stock?
The exchange symbol of HISTOGEN INC is HSTO and it is listed on the Nasdaq exchange.
On which exchange is HSTO stock listed?
HSTO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HISTOGEN INC stock?
7 analysts have analysed HSTO and the average price target is 2.04 USD. This implies a price increase of 210.03% is expected in the next year compared to the current price of 0.658. Check the HISTOGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HISTOGEN INC worth?
HISTOGEN INC (HSTO) has a market capitalization of 2.81M USD. This makes HSTO a Nano Cap stock.
How many employees does HISTOGEN INC have?
HISTOGEN INC (HSTO) currently has 7 employees.
What are the support and resistance levels for HISTOGEN INC (HSTO) stock?
HISTOGEN INC (HSTO) has a resistance level at 0.66. Check the full technical report for a detailed analysis of HSTO support and resistance levels.
Is HISTOGEN INC (HSTO) expected to grow?
The Revenue of HISTOGEN INC (HSTO) is expected to decline by -99.88% in the next year. Check the estimates tab for more information on the HSTO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HISTOGEN INC (HSTO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HSTO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HSTO, evaluating the profitability, health, valuation and growth aspects
- HISTOGEN INC (HSTO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HISTOGEN INC (HSTO) Sales and EPS estimates to see what analysts future expectations are.
- HISTOGEN INC (HSTO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HISTOGEN INC (HSTO) Insider and Institutional Ownership to learn about the owners and their transactions.
- HISTOGEN INC (HSTO) Stock Chart to make your own analysis
- HISTOGEN INC (HSTO) Latest news and press-releases to stay up to date.
Does HISTOGEN INC (HSTO) stock pay dividends?
HSTO does not pay a dividend.
When does HISTOGEN INC (HSTO) report earnings?
HISTOGEN INC (HSTO) will report earnings on 2023-11-08, after the market close.
What is the Price/Earnings (PE) ratio of HISTOGEN INC (HSTO)?
HISTOGEN INC (HSTO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.92).
HSTO Technical Analysis
HSTO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HSTO. The financial health of HSTO is average, but there are quite some concerns on its profitability.
HSTO Financial Highlights
Over the last trailing twelve months HSTO reported a non-GAAP Earnings per Share(EPS) of -2.92. The EPS increased by 41.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -89.51% | ||
| ROE | -130.43% | ||
| Debt/Equity | 0 |
HSTO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to HSTO. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 26.45% and a revenue growth -99.88% for HSTO